The Phase 1 trial aimed to investigate the PD-L1 expression determination in CRC, specifically focusing on PD-L1 IHC 22C3 pharmDx at the CPS ≥ 1 cutoff. Researchers noticed robust external lab reproducibility of PD-L1 IHC 22C3 pharmDx for PD-L1 expression in CRC at the CPS ≥ 1 cutoff. Despite advances in colorectal carcinoma […]...
Sign up for our emails
Trusted insights straight to your inbox and get the latest updates from OncWeekly
Newsletter
Advertisement
SELECT ONCOLOGY JOURNAL ARTICLES
Disparities in Survival Outcomes Among Patients With Metastatic Melanoma in Texas: Implications for Policy and Interventions in the Era of Immune Checkpoint Inhibitors
Disparities in Survival Outcomes Among Patients With Metastatic Melanoma in Texas: Implications for Policy and Interventions in the Era of Immune Checkpoint Inhibitors
Objectives: Disparities exist in the length and quality of survival from melanoma. This study evaluated, in a Texas cohort, patient factors associated with melanoma survival and examined if newer immune-oncologic agents extend survival compared with …
Disparities in Receipt of Adjuvant Immunotherapy among Stage III Melanoma Patients
Disparities in Receipt of Adjuvant Immunotherapy among Stage III Melanoma Patients
Objectives: Melanoma survival has greatly improved with the advent of immunotherapy, but unequal access to these medications may exist due to nonmedical patient factors such as insurance status, educational background, and geographic proximity to treatment. Methods: …
Safety and Efficacy of Trastuzumab Deruxtecan for Metastatic HER2+ and HER2-low Breast Cancer: An Updated Systematic Review and Meta-Analysis of Clinical Trials
Safety and Efficacy of Trastuzumab Deruxtecan for Metastatic HER2+ and HER2-low Breast Cancer: An Updated Systematic Review and Meta-Analysis of Clinical Trials
Objectives: Trastuzumab deruxtecan (T-DXd) is a novel antibody-drug conjugate (ADC) promising in treating metastatic HER2+ and HER2-low breast cancer. This updated systematic review and meta-analysis, integrating data from the latest clinical trials, aimed to evaluate …